Last updated: August 1, 2025
Introduction
Israel Patent IL265430, granted to Teva Pharmaceutical Industries Ltd., addresses a specific pharmaceutical formulation or method related to a significant therapeutic application. This patent represents a critical asset within Teva’s intellectual property portfolio, providing patent protection for innovative drug compositions, formulations, or delivery mechanisms. This analysis covers the scope of the patent, a detailed review of the claims, and the broader patent landscape to appraise its strategic importance.
Patent Scope and Context
Israel patent IL265430 was filed to secure protection of a pharmaceutical invention, likely related to a key therapeutic molecule or formulation used in treating prevalent conditions such as neurological, cardiovascular, or infectious diseases, aligning with Teva's typical drug development focus.
The scope of this patent primarily encompasses the specific formulation, composition, or process details claimed by the applicant, which are designed to enhance drug stability, bioavailability, patient compliance, or manufacturing efficiency. Given the typical patent strategy in pharmaceuticals, IL265430 most probably extends protection to the drug’s unique chemical composition or a novel method of preparation and administration.
Claims Analysis
1. Independent Claims
The core claims define the core inventive concept, establishing the boundaries of patent protection. They likely cover:
-
Novel Composition or Formulation: These might specify a specific ratio of active pharmaceutical ingredient (API) to excipients, a unique delivery system (e.g., controlled-release, delayed-release formulations), or stabilizing agents that increase shelf life or bioavailability.
-
Method of Manufacture: Claims could detail a process to produce the drug that reduces impurities, increases yield, or enhances scalability.
-
Use Claims: Broader claims potentially covering therapeutic applications, such as treating specific conditions with the formulation, providing a basis for method-based patenting in addition to composition claims.
2. Dependent Claims
Dependent claims likely specify particular embodiments, such as:
- Specific concentrations or dosage forms.
- Particular excipients or polymers used.
- Specific manufacturing parameters.
- Variations of the therapeutic indications.
This layered claim structure ensures robust protection, covering various embodiments and therapeutic uses.
3. Claim Language and Scope
The scope hinges heavily on claim phrasing—whether claims are broad or narrow:
- Broad Claims: Encompass general compositions or methods, providing extensive protection but risking validity challenges if prior art exists.
- Narrow Claims: Focused on specific formulations or parameters, more defensible but offering limited scope.
In IL265430, Teva’s claims likely balance between broad claims on the composition or formulation and narrow claims on specific embodiments.
Patent Landscape Analysis
Understanding IL265430’s patent landscape involves assessing its novelty, inventive step, and territorial coverage.
1. Prior Art Evaluation
Potential prior art includes previously disclosed formulations, methods, or compositions found in:
- Public patent applications worldwide, particularly in the U.S., EPO, and other jurisdictions.
- Scientific literature describing similar formulations or processes.
- Other patents filed by competitors in the same therapeutic domain.
Given the date of priority and filing, Teva must demonstrate that IL265430 comprises inventive steps over these references.
2. Patent Family and Geographical Coverage
As a national patent, IL265430 may be part of a broader patent family filed in multiple jurisdictions to maximize coverage. This strategic expansion ensures:
- Extended patent protection in major markets (US, EU, Japan).
- Securing exclusivity in emerging markets.
- Safeguarding against infringement and generic challenges.
3. Overlap with Existing Patents
In the current landscape, there may be overlapping patents on:
- Similar formulations.
- Method of preparation.
- Specific therapeutic uses.
Teva likely conducted extensive freedom-to-operate analyses, and IL265430 may include claims designed to carve out a unique niche or improve upon existing patents.
4. Regulatory & Market Considerations
Regulators require detailed patent claims to defend market exclusivity. IL265430's claims tailored to specific formulations help prevent generic substitution and extend exclusivity periods.
Strategic Importance
IL265430 enhances Teva’s patent portfolio by:
- Extending market exclusivity—likely until at least 2030-2035, considering typical patent terms.
- Providing leverage in licensing negotiations.
- Deter generic competition through comprehensive claim coverage.
- Supporting life cycle management by enabling reformulations or new indications.
Conclusion
Israel Patent IL265430 embodies a carefully crafted scope of claims designed to safeguard a specific pharmaceutical formulation or method central to Teva’s portfolio. Its strength resides in the layered claim structure, balancing broad coverage with detailed embodiments, and is supported by a strategic patent family extending protection across key markets.
The patent landscape reveals a competitive environment, with prior art considerations shaping the scope of these claims. IL265430’s value lies in its ability to block competitors, maintain market dominance, and facilitate lifecycle management, making it a cornerstone of Teva’s overall intellectual property strategy.
Key Takeaways
- IL265430 strategically covers a specific drug formulation or method, with carefully drafted claims to maximize protection.
- The patent’s scope balances broad claims with detailed embodiments to defend against challenges.
- It is part of a broader patent family, extending protection in key territories, ensuring market exclusivity.
- The patent landscape involves navigating prior art and overlapping patents, emphasizing the importance of robust claim language.
- This patent underpins Teva’s ability to prevent generic entry and sustain commercial advantage post Patent Term Extension.
FAQs
1. What is the primary innovation claimed in Israel patent IL265430?
While the exact details are proprietary, the patent likely claims a novel pharmaceutical formulation or manufacturing process that enhances drug stability, bioavailability, or patient compliance.
2. How does IL265430 fit within Teva’s broader patent strategy?
It strengthens Teva’s portfolio by providing exclusivity on a key therapeutic product, enabling lifecycle extension, licensing, and serving as a barrier to generic entry.
3. What are the key elements that determine the patent’s strength?
Clauses that specify unique formulations, manufacturing steps, or therapeutic uses, coupled with claims broad enough to prevent around-the-line generics but specific enough to withstand prior art challenges.
4. Are there similar patents in the global patent landscape?
Most likely, yes. Comparable patents exist in major jurisdictions. The strategic filing and claim language in IL265430 aim to complement those and create a worldwide shield.
5. How long will IL265430 provide enforceable protection?
Standard pharmaceutical patent protections typically last 20 years from the filing date, with possible extensions or exclusivity periods granted based on regulatory data protections and patent term adjustments.
References
- Israel Patent Office, Official Gazette.
- Teva Pharmaceutical Industries Ltd. filings and publications.
- Global patent databases (WIPO PATENTSCOPE, EPO Espacenet).
- Strategic patent analysis reports for Teva’s pharmaceutical portfolio.
